Transformation of a non-secretory neuroendocrine tumor to insulinoma after treatment with Sunitinib: A case report and review of the literature. J Oncol Pharm Pract 2019 Sep;25(6):1516-1519
Date
08/10/2018Pubmed ID
30089432DOI
10.1177/1078155218791309Scopus ID
2-s2.0-85052579205 (requires institutional sign-in at Scopus site) 4 CitationsAbstract
We report a case of a non-secretory neuroendocrine tumor which transformed into an insulin secreting tumor after treatment with Sunitinib. To our knowledge, this has only been described in three other cases worldwide. Previously reported case series find transformation of non-secretory neuroendocrine cancers into secretory lesions occurs in 3.4-6.8% of cases. Sunitinib is known to have the potential to lower blood glucose and induce epigenetic changes in cells of various types. We hypothesize that the mechanism for Sunitinib-induced transformation in cancer phenotype is through epigenetic changes in DNA expression within the tumor cells.
Author List
Clover T, Abdelkader A, Guru Murthy GSAuthor
Guru Subramanian Guru Murthy MD Assistant Professor in the Medicine department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
Antineoplastic AgentsCell Transformation, Neoplastic
Humans
Insulinoma
Male
Middle Aged
Neuroendocrine Tumors
Pancreatic Neoplasms